secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sagimet Biosciences Inc. (SGMT)
CIK:        0001400118
Form:       8-K
Filed at:   2024-05-15T23:59:59+00:00
Accession:  0001104659-24-061609
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sagimet Q1 2024 net loss $6.6M; cash $193.7M; FDA End-of-Phase 2 meeting in Q2; MASH Phase 3 start H2
--------------------------------------------------------------------------------

- Net loss for Q1 2024 was $6.6M, flat year-over-year; R&D expense $5.3M, G&A $3.5M.
- Cash, cash equivalents and marketable securities total $193.7M as of March 31, 2024, expected to fund operations through 2025.
- Denifanstat Phase 2b FASCINATE-2 full data to be presented as oral at EASL June 5-8, 2024.
- End-of-Phase 2 meeting with FDA anticipated in Q2 2024; Phase 3 trial start planned for second half of 2024.
- Follow-on offering in January 2024 netted $104.7M to support pipeline and general corporate purposes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1400118/000110465924061609/0001104659-24-061609-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1400118/000110465924061609/tm2414482d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-061609

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer